MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Erasca Inc

Suletud

1.49 0.68

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.46

Max

1.6

Põhinäitajad

By Trading Economics

Sissetulek

1.3M

-31M

Töötajad

103

EBITDA

-750K

-36M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+200.69% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

8. aug 2025

Turustatistika

By TradingEconomics

Turukapital

20M

414M

Eelmine avamishind

0.81

Eelmine sulgemishind

1.49

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

Erasca Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

18. juuli 2025, 21:01 UTC

Tulu

Charles Schwab Profit Jumps on Tariff Trading Surge -- 2nd Update

18. juuli 2025, 20:50 UTC

Market Talk
Tulu

Tech, Media & Telecom Roundup: Market Talk

18. juuli 2025, 20:50 UTC

Market Talk
Tulu

Auto & Transport Roundup: Market Talk

18. juuli 2025, 20:50 UTC

Market Talk
Tulu

Basic Materials Roundup: Market Talk

18. juuli 2025, 20:46 UTC

Tulu

Strong Earnings Fuel Stock-Market Records This Week -- WSJ

18. juuli 2025, 20:39 UTC

Omandamised, ülevõtmised, äriostud

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18. juuli 2025, 20:36 UTC

Tulu

3M Gives Investors a 'Beat and Raise.' The Stock Is Rising. -- Barrons.com

18. juuli 2025, 20:16 UTC

Omandamised, ülevõtmised, äriostud

Chevron-Hess Deal Close Is Good News for Wall Street's Takeover Arbitragers -- Barrons.com

18. juuli 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18. juuli 2025, 20:02 UTC

Market Talk

Gold Higher to Close Out Week -- Market Talk

18. juuli 2025, 19:14 UTC

Market Talk

U.S. Natural Gas Futures Post Weekly Gains -- Market Talk

18. juuli 2025, 19:06 UTC

Market Talk

Oil Futures Snap Two-Week Winning Streak -- Market Talk

18. juuli 2025, 18:24 UTC

Tulu

These Stocks Are Moving the Most Today: Netflix, Sarepta, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, and More -- Barrons.com

18. juuli 2025, 18:19 UTC

Tulu

American Express Shares Drop as Earnings Beat, Record Revenue Fail to Impress -- Barrons.com

18. juuli 2025, 18:11 UTC

Omandamised, ülevõtmised, äriostud

Oil CEOs Get Their Revenge on Biden's Antitrust Enforcers -- WSJ

18. juuli 2025, 18:11 UTC

Tulu

Netflix Earnings Show That YouTube Is the Streamer to Fear -- Barrons.com

18. juuli 2025, 17:35 UTC

Market Talk

U.S. Oil Rig Count Falls by 2 to 422 -- Market Talk

18. juuli 2025, 16:29 UTC

Market Talk

Crude Rally on EU's Russia Sanctions Peters Out -- Market Talk

18. juuli 2025, 16:28 UTC

Omandamised, ülevõtmised, äriostud

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18. juuli 2025, 16:22 UTC

Tulu

These Stocks Are Moving the Most Today: Netflix, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, Sarepta, and More -- Barrons.com

18. juuli 2025, 16:20 UTC

Market Talk
Tulu

Financial Services Roundup: Market Talk

18. juuli 2025, 16:20 UTC

Market Talk
Tulu

Tech, Media & Telecom Roundup: Market Talk

18. juuli 2025, 16:20 UTC

Market Talk
Tulu

Auto & Transport Roundup: Market Talk

18. juuli 2025, 16:20 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Energy & Utilities Roundup: Market Talk

18. juuli 2025, 16:20 UTC

Market Talk
Tulu

Basic Materials Roundup: Market Talk

18. juuli 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18. juuli 2025, 16:04 UTC

Tulu

Charles Schwab Profit Jumps on Tariff Trading Surge -- Update

18. juuli 2025, 15:58 UTC

Market Talk

Global Equities Roundup: Market Talk

18. juuli 2025, 15:58 UTC

Market Talk

Aluminum Gains on U.S. Dollar Weakness, Scrap Imports -- Market Talk

18. juuli 2025, 15:47 UTC

Market Talk
Tulu

Netflix Shifting Focus to Engagement with New Content -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Erasca Inc Prognoos

Hinnasiht

By TipRanks

200.69% tõus

12 kuu keskmine prognoos

Keskmine 4.33 USD  200.69%

Kõrge 6 USD

Madal 3 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Erasca Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

3

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

1.39 / 1.44Toetus ja vastupanu

Lühikene perspektiiv

Bearish Evidence

Keskpikk perspektiiv

Weak Bearish Evidence

Pikk perspektiiv

Very Strong Bearish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.